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Background
Hepatitis C virus infection is the main cause of chronic
liver disease, and patients are at risk of developing liver
cirrhosis and hepatocellular carcinoma. The treatment
in CHC is the combination of pegylated interferon 2a
(peg-IFN) and ribavirin (RBV), the standard therapy
with 24 to 48 weeks regimen. Cutaneous adverse effects
are common, with a higher incidence in combination
therapy than in IFN alone, and when serious, disconti-
nuation of therapy is mandatory.
Case report
We report the case of a woman who developed an
exanthematous drug eruption during peg-IFN and RBV
combination therapy for CHC. The patient was clinically
examined and we performed routine tests and PCR for
HCV-RNA.
A 54-year-old woman with chronic hepatitis C (HCV
viral load of 1,432,722 IU/mL), presented with general-
ized rash and pruritus, which appeared on the upper
extremities and trunk after receiving her eighth weekly
injection of peg-IFN 2a (180 mcg/week), in combination
with daily oral RBV (1000 mg/day) and spread to the
face, palms and lower extremities.
Dermatological examination revealed an erythematous
maculopapular eruption, symmetrically distributed over
the trunk, extremities, cheeks and ears, associating mod-
erate pruritus and xerosis. On her left thigh, the patient
presented an ill-defined, slightly pruritic, erythematous
round patch, localized to the point of administration.
On both palms and fingers, there were multiple sym-
metric, firm, deep-seated vesicles, with intense pruritus.
The patient was treated with desloratadinum and
methylprednisolone aceponate ointment 0.1%, for
10 days, with complete clearance of the eruption and ces-
sation of pruritus. The localized patch at the site of injec-
tion healed within a month with diffuse desquamation
and mild postinflammatory pigmentation. During follow-
up, the patient presented with new erythematous patches
at the administration point of peg-IFN. The patient
reported lacking appetite, feeling weak, nauseous and
dizzy.
After 12 weeks treatment, ALT and AST, with initially
high values, normalized. However, considering the low
virologic response (viral load 57,126 IU/mL), the patient’s
overall clinical status, low prothrombin index, low body
mass index and significant blood count abnormalities
(anemia, thrombocytopenia and neutropenia), we decided
to discontinue therapy, without new lesions at follow-up.
Conclusion
The dermatological diagnosis was exanthematous drug
eruption, which was considered a side effect of combina-
tion therapy with peg-IFN and RBV, due to the time link
between the development of lesions and the CHC ther-
apy, lack of other cause of eruption, and complete resolu-
tion after treatment withdrawal. Furthermore, the patient
is still monitored and we consider other treatment
options.
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